Aurinia Pharmaceuticals (AUPH) Other financing activities (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Other financing activities data on file, last reported at $713000.0 in Q1 2026.

• Quarterly Other financing activities fell 92.32% year-over-year to $713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 53.01% YoY) and the FY2025 annual result came in at $14.2 million, up 73.34% from the prior year.
• Other financing activities declined to $713000.0 in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.3 million in Q1 2025 to a low of -$184000.0 in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.3 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 102.04% — and 2023, when it soared 858.15%.
• Tracing AUPH's Other financing activities over 5 years: stood at -$184000.0 in 2022, then soared by 858.15% to $1.4 million in 2023, then increased by 18.21% to $1.6 million in 2024, then slipped by 2.55% to $1.6 million in 2025, then slumped by 55.63% to $713000.0 in 2026.
• The last three Other financing activities figures came in at $713000.0 (Q1 2026), $1.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.